Wysa develops AI-assisted mental-health support for consumers, employers, insurers and healthcare providers. Its conversational app combines clinician-designed cognitive behavioural exercises, mindfulness and wellbeing tools with access to human coaching and care pathways. Enterprise deployments support referral, between-session engagement and integration with existing benefits and clinical services. Wysa Copilot combines digital exercises, messaging and patient tracking for clinicians. Current services also include collaborative care through April Health and physical therapy through Kins, expanding its combination of digital and human care. The business has operations in Boston, Bengaluru and London; published legal notices identify Touchkin eServices and worldwide affiliates, including Wysa entities, rather than an assumed single-country legal merger. The company publishes research on engagement and outcomes across several settings; these studies do not establish guaranteed benefit for every person or deployment. In May2022, Wysa announced FDA Breakthrough Device Designation for a smartphone conversational CBT agent for adults with chronic musculoskeletal pain and associated depression and anxiety. That designation supports development and review and is not FDA marketing approval. The general wellbeing product is not crisis care or a substitute for medical advice. Public funding includes a USD5.5million Series A announced in May2021, USD20million financing announced in July2022, and a2026 Wellcome-supported GBP5.3million research project for adolescent girls in rural India. The research grant is not equity or unrestricted commercial financing.
Founded 2015
Team
Aishwarya KamathAI product contributor (published research; current employment unverified)
